Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Governments are increasingly reliant on consulting firms. Critics says it's often to their detriment

Critics say governments are outsourcing their own knowledge and activities to consulting firms, yet these firms aren't held to the same standards as the public sector.

ABC News

‘Near-automatic sign off’ – Hunt pledges £10m to speed up access to new drugs

The Chancellor said that £10 million would be awarded to help streamline approvals for new medical products.

The Independent UK

The Smartest Stock to Buy for Under $50 Now

Pharma giant Pfizer (PFE) had a successful fiscal year 2022 with record-breaking revenue and earnings. Moreover, its recent acquisition should boost its portfolio and revenue. Given the market volatility, this fundamentally strong stock might be an ideal buy for under $50. Keep reading.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Biotech Stocks And The SVB Collapse — Here's What We Know

The collapse of SVB will leave early-stage biotech companies in a funding dearth. But big-name biotech stocks will emerge largely untouched.

Investors Business Daily

1 Stock to Buy This Week and Hold for the Next 20 Years

Although the stock market remains highly volatile, investing for the long term can never be timed perfectly. I believe buying fundamentally strong biopharmaceutical major Bristol-Myers Squibb (BMY) now for the long term could be wise, given the solid prospects of its new drug launches. Read more….

StockNews.com

Novo Nordisk to slash insulin price by up to 75% in push for affordable diabetes treatments

The brand is the latest to plan dramatic price cuts for the diabetes drug

The Independent UK

Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment

Amylyx's new ALS treatment crushed Wall Street's fourth-quarter expectations, pushing AMLX stock briefly above its 50-day line Tuesday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Rwanda welcomes Africa's first mobile vaccine-production units

Six mobile vaccine-production units developed by German pharmaceutical company BioNTech have arrived in Rwanda. This is the first such shipment to Africa as the continent seeks to boost local production of mRNA vaccines.

Radio France Internationale

The VA will pay for some to get new Alzheimer’s drug

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

Tribune News Service

Vertex Pharmaceuticals Stock Gets Technical Rating Upgrade

Vertex Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Pfizer to pay $43 billion for Seagen, set post-COVID course

Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma.

Tribune News Service

This Big Pharma Stock Is a Clear Buy in 2023

With interest rates expected to be higher than originally anticipated and fears of a looming recession weighing heavily on investors’ decisions, the stock market is expected to remain under pressure this year. Amid this backdrop, it could be wise for investors to invest in Johnson & Johnson (JNJ) due to…

StockNews.com

2 Top Biotech Stocks to Buy in March

The biotech industry is expected to witness solid growth amid impressive advancements and government initiatives. Moreover, the biotech sector tends to be more defensive than others during market downturns. So, fundamentally sound biotech stocks Amgen (AMGN) and Biogen (BIIB) might be ideal buys now. Keep reading.

StockNews.com

Pfizer to buy cancer drugmaker Seagen in $43 billion deal

Pfizer Inc. agreed to purchase cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, gaining the company’s antibody drugs that fight tumors.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Ballotpedia

Democratic attorneys general sue Biden administration over FDA abortion pill regulation

A group of 12 Democratic state attorneys general filed a lawsuit in the United States District Court for the Eastern District of Washington against the Food and Drug Administration (FDA) on Feb. 23, 2023, arguing that the agency’s regulations on the abortion-inducing drug mifepristone violate state sovereignty by limiting the…

Investors Business Daily

Dow Jones Reverses On SVB Rescue Plan; First Republic, Charles Schwab Crash On Bank Fears

The Dow Jones fell Monday, as the FDIC guaranteed all deposits of SVB Financial. First Republic crashed 75% on ongoing bank fears.

The Independent UK

Pfizer will spend $43 billion to acquire Seagen

Pfizer will spend about $43 billion to buy Seagen and broaden its reach into cancer treatments, the pharmaceutical giant said Monday

The Independent UK

FDA approves world’s first fast-acting nasal spray to treat migraines

Drug marks ‘significant breakthrough’ for people with migraine who need freedom from pain

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biotech, Banking Stocks Tumble As Federal Officials Seize SVB Deposits

The federal government's takeover of Silicon Valley Bank on Friday sent shock waves through the medical sector and hammered biotech stocks.

Investors Business Daily

Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle

Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble.

StockNews.com

5 Best Pharma Stocks to Buy Right Now

The pharma industry has experienced tremendous growth in recent years and should continue to grow amid the integration of advanced technologies. Hence, pharma stocks Eli Lilly (LLY), Takeda Pharmaceutical (TAK), Catalyst Pharmaceuticals (CPRX), Poseida Therapeutics (PSTX), and Voyager Therapeutics (VYGR) might be worth buying right now. Read on.

Los Angeles Times

Drug to prevent preterm birth pulled from market, years after it was shown ineffective

A pharmaceutical company selling the only drug approved to prevent preterm birth said Tuesday that it would withdraw the medicine from the market.

The Independent UK

Chinese firm awarded contract after attempting to hack NHS data, minister claims

George Freeman claimed the BGI Group was a “danger point” in science and technology

The Independent UK

Maker of unproven birth drug Makena to pull from US market

The maker of an unproven drug intended to prevent premature births says it will voluntarily remove the product from the United States

Investors Business Daily

Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race

Sanofi stock could shine in 2023 as the French pharma tees up a rival to Pfizer's experimental RSV vaccine for newborn babies.

1 … 55 56 57 58

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.